Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$13.32 USD
-0.11 (-0.82%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $13.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
TEVA 13.32 -0.11(-0.82%)
Will TEVA be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TEVA
J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics
Zacks Industry Outlook Highlights Amphastar, Teva and Dr. Reddy's
Other News for TEVA
Prepare for Takeoff With Perrigo
The Generic Drugs Antitrust Case
Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors